Shares of Argos Therapeutics Inc. (NASDAQ:ARGS) were up 4.8% on Thursday . The stock traded as high as $4.21 and last traded at $4.18, with a volume of 394,533 shares traded. The stock had previously closed at $3.99.

Several analysts recently weighed in on ARGS shares. Needham & Company LLC restated a “buy” rating on shares of Argos Therapeutics in a research report on Saturday, April 23rd. Zacks Investment Research downgraded Argos Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, May 5th. FBR & Co restated a “buy” rating on shares of Argos Therapeutics in a research report on Saturday, May 14th. Finally, Piper Jaffray Cos. restated an “overweight” rating and set a $11.00 price objective on shares of Argos Therapeutics in a research report on Monday, June 20th. Eight equities research analysts have rated the stock with a buy rating, The company currently has a consensus rating of “Buy” and an average target price of $11.50.

The stock’s market capitalization is $108.96 million. The stock has a 50-day moving average price of $5.57 and a 200 day moving average price of $5.84.

Argos Therapeutics (NASDAQ:ARGS) last released its earnings results on Wednesday, August 10th. The biopharmaceutical company reported ($0.48) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.43) by $0.05. Equities analysts forecast that Argos Therapeutics Inc. will post ($1.49) earnings per share for the current year.

Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.